Skip to main content

Table 4 Alzheimer’s cerebrospinal fluid biomarkers at baseline

From: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease

 

Overall cohort

rpAD

Non-rpAD

P-value (after MLRA)

Tau (pg/ml)

median (IQR)

514

(387)

629

(562.3)

476

(338.5)

0.014*

(0.074)

P-Tau (pg/ml)

median (IQR)

79

(40)

85.5

(54.55)

77

(37)

0.090

(0.059)

Tau-ratio (P-Tau/Tau)

median (IQR)

0.16

(0.09)

0.16

(0.1)

0.17

(0.08)

0.571

(0.336)

Aβ1-42 (pg/ml)

median (IQR)

582

(343)

500

(274)

614

(338)

0.008*

(0.048)*

Aβ1-40modified (pg/ml)a

median (IQR)

9415

(4152)

9145

(4035)

9459

(4218)

0.921

(0.339)

Aß-ratiomodfieda

median (IQR)

0.62

(0.41)

0.54

(0.25)

0.65

(0.45)

0.008*

(0.038)*

Tau/Aβ1-42- Ratio

median (IQR)

0.9

(0.94)

1.32

(1.07)

0.75

(0.77)

< 0.001*

(0.004)*

P-Tau/Aβ1-42- Ratio

median (IQR)

0.15

(0.13)

0.18

(0.18)

0.14

(0.13)

0.007*

(0.004)*

  1. aDue to a change in laboratory methods the Aβ1-40 values had to be modified as described in the “Methods” section
  2. Abbreviations: rpAD rapidly progressive Alzheimer’s disease, MLRA multiple logistic regression analysis, IQR interquartile range, P-Tau hyperphosphorylated Tau protein
  3. *p-values below significance threshold of 0.05